Verisante Technology Inc. V.VRS

Profit analysis

[AnalyticalTrader]

There is a shortage of asks.  Interested investors have small windows to get in on VRS in October with the page-turning HC approval fully expected to meet the standard wait-time.  For those who wonder about timing, here is a preliminary analysis that, I believe, many of you have done so already.


Initial Position------Target Prices--------------Gain----------
0.20                          2.6/5                         1200%/2400%
0.50                          2.6/5                         420%/900%
0.70                          2.6/5                         271.43%/614.29%
0.80                          2.6/5                         225%/525%
0.85                          2.6/5                         205.88%/488.2%
0.90                          2.6/5                         173.68%/455.56%
1.50                          2.6/5                         73.33%/233.33%
2.00                          2.6/5                         30%/150%


Current support: 0.82


Health Canada (HC) approval submission date: Oct 6
Average wait-time: 15 days


Three more anticipated milestones:
CE Mark submission: shortly; "Verisante anticipates submitting our Technical File in October." 
Date: October
Australia submission: expected after HC approval

Date: October
FDA discussion: immediately following HC approval
Date: October


Horizon:

2.6$: Q3/4 2011 (CDN/AUS/EU launches)
5$: Q3 2012 (US launch)
10$:Q3 2013 (China launch)